Trump announces trade deal with EU following months of negotiations
CARLSBAD, CA - Palisade Bio, Inc. (NASDAQ:PALI), a clinical-stage biopharmaceutical company with a market capitalization of $3.46 million, has presented positive preclinical data on PALI-2108, a colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug, at Digestive Disease Week (DDW) 2025. According to InvestingPro analysis, the company maintains a strong liquidity position with a current ratio of 3.24, indicating robust short-term financial stability. The data, from a study on a mouse model of colitis, indicate that PALI-2108 may offer a favorable safety profile and efficacy in treating ulcerative colitis (UC), a chronic inflammatory bowel disease.
The preclinical study demonstrated that PALI-2108, administered orally, effectively reduced colon tissue PDE4B expression in a dose-dependent manner, leading to increased cAMP levels and suppression of TNF-α, a cytokine involved in systemic inflammation. These results suggest that the drug could potentially alleviate symptoms associated with UC.
During the DDW session held from May 3 to May 6 in San Diego, California, Palisade Bio’s first poster, which was recognized as a Poster of Distinction, detailed how PALI-2108 improved clinical parameters of colitis, including the Disease Activity Index (DAI), body weight, and colon length. The study also compared the efficacy of PALI-2108 with standard treatments such as cyclosporine A and apremilast, with PALI-2108 showing dose-dependent effects with minimal CNS toxicity.
In addition to the efficacy data, pharmacokinetic modeling from healthy volunteers suggested that PALI-2108 has favorable absorption and bioavailability, supporting its potential for clinical use. The company is currently advancing a Phase 1a/b study of PALI-2108, focusing on safety, tolerability, pharmacokinetics, and pharmacodynamics. Topline data from the completed Phase 1a portion of the study is expected by the end of May 2025.
Palisade Bio also presented a second poster at DDW, proposing the potential anti-fibrotic efficacy of PALI-2108 in intestinal fibrosis through local PDE4 inhibition.
This news comes as Palisade Bio continues to develop novel therapeutics for autoimmune, inflammatory, and fibrotic diseases. The company’s approach aims to transform the treatment landscape for these conditions.
The information in this article is based on a press release statement from Palisade Bio. Investors interested in the ongoing clinical trials for PALI-2108 can find more information under the identifier NCT06663605 at clinicaltrials.gov. With the company’s next earnings report scheduled for May 13, 2025, InvestingPro subscribers can access 10+ additional exclusive tips and comprehensive financial metrics to make informed investment decisions. Based on InvestingPro’s Fair Value analysis, PALI currently appears undervalued despite its recent price decline, making it an interesting watch for value investors. Check out more undervalued opportunities at Most Undervalued Stocks.
In other recent news, Palisade Bio, Inc. has successfully completed the Phase 1a trials for its drug PALI-2108, designed to treat Ulcerative Colitis. The trials reported no serious adverse events, indicating that the drug is well-tolerated. The company is now progressing with the Phase 1b UC patient cohort and expects to release topline data by the first half of 2025. Additionally, Palisade Bio will present data on PALI-2108 at the upcoming Digestive Disease Week 2025, where its abstract has been recognized in the top 10% for poster presentation. The company will showcase the drug’s potential anti-fibrotic efficacy and its bioactivation in the colon. In financial news, Palisade Bio has secured 1.39 million Canadian dollars in tax credits from Canada to support pre-clinical studies conducted in Montreal. This funding is part of a joint development agreement with Giiant Pharma, Inc. The company continues to emphasize the dependency on PALI-2108’s success and acknowledges the risks and uncertainties associated with its clinical development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.